{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:44:39Z","timestamp":1788414279802,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T00:00:00Z","timestamp":1337212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11926-012-0259-1","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T00:40:59Z","timestamp":1337128859000},"page":"349-357","source":"Crossref","is-referenced-by-count":26,"title":["Altered Bone Biology in Psoriatic Arthritis"],"prefix":"10.1007","volume":"14","author":[{"given":"Homaira","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,17]]},"reference":[{"issue":"12","key":"259_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrrheum.2009.217","volume":"5","author":"H Takayanagi","year":"2009","unstructured":"Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol. 2009;5(12):667\u201376. doi:\n                    10.1038\/nrrheum.2009.217\n                    \n                  .","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"259_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5435\/JAAOS-20-01-028","volume":"20","author":"MS Day","year":"2012","unstructured":"Day MS, Nam D, Goodman S, Su EP, Figgie M. Psoriatic arthritis. J Am Acad Orthop Surg. 2012;20(1):28\u201337. doi:\n                    10.5435\/JAAOS-20-01-028\n                    \n                  .","journal-title":"J Am Acad Orthop Surg"},{"issue":"5","key":"259_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59(5):686\u201391. doi:\n                    10.1002\/art.23568\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"259_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1136\/ard.2010.132423","volume":"70","author":"S Finzel","year":"2011","unstructured":"Finzel S, Englbrecht M, Engelke K, Stach C, Schett G. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis. 2011;70(1):122\u20137. doi:\n                    10.1136\/ard.2010.132423\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"key":"259_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.immunol.24.021605.090646","volume":"24","author":"MC Walsh","year":"2006","unstructured":"Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33\u201363. doi:\n                    10.1146\/annurev.immunol.24.021605.090646\n                    \n                  .","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"259_CR6","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10875-009-9316-6","volume":"29","author":"T Nakashima","year":"2009","unstructured":"Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol. 2009;29(5):555\u201367. doi:\n                    10.1007\/s10875-009-9316-6\n                    \n                  .","journal-title":"J Clin Immunol"},{"issue":"12","key":"259_CR7","first-page":"93","volume":"21","author":"T Nakashima","year":"2011","unstructured":"Nakashima T, Hayashi M, Takayanagi H. Bone and calcium update; bone research update. Osteoclastogenesis and osteoimmunology. Clin Calcium. 2011;21(12):93\u2013102.","journal-title":"Clin Calcium"},{"issue":"7","key":"259_CR8","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1172\/JCI46262","volume":"121","author":"D Jones","year":"2011","unstructured":"Jones D, Glimcher LH, Aliprantis AO. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest. 2011;121(7):2534\u201342. doi:\n                    10.1172\/Jci46262\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"12","key":"259_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nrrheum.2011.156","volume":"7","author":"R Lories","year":"2011","unstructured":"Lories R. The balance of tissue repair and remodeling in chronic arthritis. Nat Rev Rheumatol. 2011;7(12):700\u20137. doi:\n                    10.1038\/nrrheum.2011.156\n                    \n                  .","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"259_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/BOR.0b013e32832c6ab9","volume":"21","author":"D McGonagle","year":"2009","unstructured":"McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol. 2009;21(4):340\u20137. doi:\n                    10.1097\/BOR.0b013e32832c6ab9\n                    \n                  .","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"259_CR11","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/j.1365-2362.2011.02545.x","volume":"41","author":"G Schett","year":"2011","unstructured":"Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Investig. 2011;41(12):1361\u20136. doi:\n                    10.1111\/j.1365-2362.2011.02545.x\n                    \n                  .","journal-title":"Eur J Clin Investig"},{"issue":"2","key":"259_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13(2):156\u201363. doi:\n                    10.1038\/nm1538\n                    \n                  .","journal-title":"Nat Med"},{"key":"259_CR13","doi-asserted-by":"publisher","unstructured":"Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2011. doi:\n                    10.1136\/annrheumdis-2011-200216\n                    \n                  .","DOI":"10.1136\/annrheumdis-2011-200216"},{"issue":"1","key":"259_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/art.27231","volume":"62","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, et al. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum. 2010;62(1):150\u20138. doi:\n                    10.1002\/art.27231\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"1","key":"259_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/cr.2008.302","volume":"19","author":"X Guo","year":"2009","unstructured":"Guo X, Wang XF. Signaling cross-talk between TGF-beta\/BMP and other pathways. Cell Res. 2009;19(1):71\u201388. doi:\n                    10.1038\/Cr.2008.302\n                    \n                  .","journal-title":"Cell Res"},{"issue":"2","key":"259_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.7150\/ijbs.2929","volume":"8","author":"G Chen","year":"2012","unstructured":"Chen G, Deng C, Li YP. TGF-beta and BMP signaling in osteoblast differentiation and bone formation. Int J Biol Sci. 2012;8(2):272\u201388. doi:\n                    10.7150\/ijbs.2929\n                    \n                  .","journal-title":"Int J Biol Sci"},{"issue":"3","key":"259_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/ncb2022","volume":"12","author":"T Qiu","year":"2010","unstructured":"Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol. 2010;12(3):224\u201334. doi:\n                    10.1038\/ncb2022\n                    \n                  .","journal-title":"Nat Cell Biol"},{"issue":"2","key":"259_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0002-9440(10)63144-6","volume":"164","author":"K Redlich","year":"2004","unstructured":"Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, et al. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol. 2004;164(2):543\u201355. doi:\n                    10.1016\/S0002-9440(10)63144-6\n                    \n                  .","journal-title":"Am J Pathol"},{"issue":"6","key":"259_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI23738","volume":"115","author":"RJU Lories","year":"2005","unstructured":"Lories RJU, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005;115(6):1571\u20139. doi:\n                    10.1172\/Jci23738\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"2","key":"259_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1359\/jbmr.090806","volume":"25","author":"N Kamiya","year":"2010","unstructured":"Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM, et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(2):200\u201310. doi:\n                    10.1359\/jbmr.090806\n                    \n                  .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"4","key":"259_CR21","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/art.30153","volume":"63","author":"K Gelse","year":"2011","unstructured":"Gelse K, Beyer C. The prostaglandin E(2) system: a toolbox for skeletal repair? Arthritis Rheum. 2011;63(4):871\u20133. doi:\n                    10.1002\/art.30153\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"8","key":"259_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1172\/Jci200215681","volume":"110","author":"XP Zhang","year":"2002","unstructured":"Zhang XP, Schwarz EM, Young DA, Puzas JE, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair (vol 109, pg 1405, 2002). J Clin Invest. 2002;110(8):1211. doi:\n                    10.1172\/Jci200215681\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"11","key":"259_CR23","doi-asserted-by":"publisher","first-page":"6736","DOI":"10.1073\/pnas.1037343100","volume":"100","author":"VM Paralkar","year":"2003","unstructured":"Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003;100(11):6736\u201340. doi:\n                    10.1073\/pnas.1037343100\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"259_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756\u201365. doi:\n                    10.1002\/art.21054\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"10","key":"259_CR25","first-page":"S510","volume":"63","author":"N Haroon","year":"2011","unstructured":"Haroon N, Shen H, Carty A, Anton A, Cook RJ, Inman RD. Continuance of non-steroidal anti-inflammatory drugs may reduce radiographic progression in ankylosing spondylitis patients on biological therapy. Arthritis Rheum. 2011;63(10):S510\u2013S","journal-title":"Arthritis Rheum"},{"issue":"6","key":"259_CR26","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/art.27399","volume":"62","author":"S Bluml","year":"2010","unstructured":"Bluml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum. 2010;62(6):1608\u201319. doi:\n                    10.1002\/art.27399\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"4","key":"259_CR27","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","volume":"7","author":"H Takayanagi","year":"2007","unstructured":"Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007;7(4):292\u2013304. doi:\n                    10.1038\/nri2062\n                    \n                  .","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"259_CR28","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1172\/JCI45913","volume":"121","author":"AD Barrow","year":"2011","unstructured":"Barrow AD, Raynal N, Andersen TL, Slatter DA, Bihan D, Pugh N, et al. OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest. 2011;121(9):3505\u201316. doi:\n                    10.1172\/JCI45913\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"6984","key":"259_CR29","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/nature02444","volume":"428","author":"T Koga","year":"2004","unstructured":"Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004;428(6984):758\u201363. doi:\n                    10.1038\/nature02444\n                    \n                  .","journal-title":"Nature"},{"issue":"4","key":"259_CR30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood-2010-11-317016","volume":"118","author":"T Ormsby","year":"2011","unstructured":"Ormsby T, Schlecker E, Ferdin J, Tessarz AS, Angelisova P, Koprulu AD, et al. Btk is a positive regulator in the TREM-1\/DAP12 signaling pathway. Blood. 2011;118(4):936\u201345. doi:\n                    10.1182\/blood-2010-11-317016\n                    \n                  .","journal-title":"Blood"},{"issue":"2","key":"259_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.imlet.2007.11.021","volume":"116","author":"AS Tessarz","year":"2008","unstructured":"Tessarz AS, Cerwenka A. The TREM-1\/DAP12 pathway. Immunol Lett. 2008;116(2):111\u20136. doi:\n                    10.1016\/j.imlet.2007.11.021\n                    \n                  .","journal-title":"Immunol Lett"},{"issue":"17","key":"259_CR32","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.1074\/jbc.M708935200","volume":"283","author":"SH Lee","year":"2008","unstructured":"Lee SH, Kim T, Jeong D, Kim N, Choi Y. The tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturation. J Biol Chem. 2008;283(17):11526\u201334. doi:\n                    10.1074\/jbc.M708935200\n                    \n                  .","journal-title":"J Biol Chem"},{"issue":"1","key":"259_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/jbmr.210","volume":"26","author":"L Danks","year":"2010","unstructured":"Danks L, Workman S, Webster D, Horwood NJ. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner Res. 2010;26(1):182\u201392. doi:\n                    10.1002\/jbmr.210\n                    \n                  .","journal-title":"J Bone Miner Res"},{"key":"259_CR34","doi-asserted-by":"publisher","unstructured":"Ch'ng ES, Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer. 2010;9. doi:Artn 251; doi:\n                    10.1186\/1476-4598-9-251","DOI":"10.1186\/1476-4598-9-251"},{"issue":"11","key":"259_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.2499","volume":"17","author":"X Cao","year":"2011","unstructured":"Cao X. Targeting osteoclast-osteoblast communication. Nat Med. 2011;17(11):1344\u20136. doi:\n                    10.1038\/nm.2499\n                    \n                  .","journal-title":"Nat Med"},{"issue":"11","key":"259_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga T, Shinohara M, Komatsu N, Bito H, Kodama T, Friedel RH, et al. Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med. 2011;17(11):1473\u2013U181. doi:\n                    10.1038\/Nm.2489\n                    \n                  .","journal-title":"Nat Med"},{"issue":"6","key":"259_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/ard.2010.142539","volume":"70","author":"F McQueen","year":"2011","unstructured":"McQueen F, Lloyd R, Doyle A, Robinson E, Lobo M, Exeter M, et al. Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) study. Ann Rheum Dis. 2011;70(6):1091\u20134. doi:\n                    10.1136\/ard.2010.142539\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"259_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000258049","volume":"220","author":"FM Solivetti","year":"2010","unstructured":"Solivetti FM, Elia F, Teoli M, De Mutiis C, Chimenti S, Berardesca E, et al. Role of contrast-enhanced ultrasound in early diagnosis of psoriatic arthritis. Dermatology. 2010;220(1):25\u201331. doi:\n                    10.1159\/000258049\n                    \n                  .","journal-title":"Dermatology"},{"key":"259_CR39","doi-asserted-by":"publisher","unstructured":"Anandarajah A. Imaging in psoriatic arthritis. Clin Rev Allergy Immunol. 2012. doi:\n                    10.1007\/s12016-012-8304-4\n                    \n                  .","DOI":"10.1007\/s12016-012-8304-4"},{"issue":"5","key":"259_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.semarthrit.2010.05.009","volume":"40","author":"M Gutierrez","year":"2011","unstructured":"Gutierrez M, Filippucci E, De Angelis R, Salaffi F, Filosa G, Ruta S, et al. Subclinical entheseal involvement in patients with psoriasis: an ultrasound study. Semin Arthritis Rheum. 2011;40(5):407\u201312. doi:\n                    10.1016\/j.semarthrit.2010.05.009\n                    \n                  .","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"259_CR41","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1136\/ard.2010.148395","volume":"70","author":"S Finzel","year":"2011","unstructured":"Finzel S, Rech J, Schmidt S, Engelke K, Englbrecht M, Stach C, et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion. Ann Rheum Dis. 2011;70(9):1587\u201393. doi:\n                    10.1136\/ard.2010.148395\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"259_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15100","volume":"15","author":"M Rodgers","year":"2011","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Tech Assess. 2011;15(10):i\u2013xxi, 1\u2013329. doi:\n                    10.3310\/hta15100","journal-title":"Health Tech Assess"},{"issue":"2","key":"259_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00774-009-0127-x","volume":"28","author":"Y Eguchi","year":"2010","unstructured":"Eguchi Y, Wakitani S, Imai Y, Naka Y, Hashimoto Y, Nakamura H, et al. Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation. J Bone Miner Metab. 2010;28(2):157\u201364. doi:\n                    10.1007\/s00774-009-0127-x\n                    \n                  .","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"259_CR44","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2007.076091","volume":"67","author":"AP Anandarajah","year":"2008","unstructured":"Anandarajah AP, Schwarz EM, Totterman S, Monu J, Feng CY, Shao T, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67(3):296\u2013301. doi:\n                    10.1136\/ard.2007.076091\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"259_CR45","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279\u201389. doi:\n                    10.1002\/art.21306\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"8","key":"259_CR46","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64(8):1150\u20137. doi:\n                    10.1136\/ard.2004.032268\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"9227","key":"259_CR47","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385\u201390. doi:\n                    10.1016\/S0140-6736(00)02530-7\n                    \n                  .","journal-title":"Lancet"},{"issue":"5","key":"259_CR48","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/ard.2009.112920","volume":"69","author":"RK Dore","year":"2010","unstructured":"Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis. 2010;69(5):872\u20135. doi:\n                    10.1136\/ard.2009.112920\n                    \n                  .","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"259_CR49","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a 12-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299\u2013309. doi:\n                    10.1002\/art.23417\n                    \n                  .","journal-title":"Arthritis Rheum"},{"issue":"4","key":"259_CR50","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/acr.20004","volume":"62","author":"A Deodhar","year":"2010","unstructured":"Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res. 2010;62(4):569\u201374. doi:\n                    10.1002\/acr.20004\n                    \n                  .","journal-title":"Arthritis Care Res"},{"issue":"12","key":"259_CR51","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3109\/00498254.2011.604745","volume":"41","author":"M Hoffmann","year":"2011","unstructured":"Hoffmann M, Kumar G, Schafer P, Cedzik D, Capone L, Fong KL, et al. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica Fate Foreign Compd Biol Syst. 2011;41(12):1063\u201375. doi:\n                    10.3109\/00498254.2011.604745\n                    \n                  .","journal-title":"Xenobiotica Fate Foreign Compd Biol Syst"},{"issue":"3","key":"259_CR52","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/ar3041","volume":"12","author":"FE McCann","year":"2010","unstructured":"McCann FE, Palfreeman AC, Andrews M, Perocheau DP, Inglis JJ, Schafer P, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107. doi:\n                    10.1186\/ar3041\n                    \n                  .","journal-title":"Arthritis Res Ther"},{"key":"259_CR53","doi-asserted-by":"publisher","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012. doi:\n                    10.1016\/j.bcp. 2012.01.001\n                    \n                  .","DOI":"10.1016\/j.bcp.2012.01.001"},{"issue":"7","key":"259_CR54","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234\u201343. doi:\n                    10.4049\/jimmunol.1003668\n                    \n                  .","journal-title":"J Immunol"},{"issue":"10","key":"259_CR55","first-page":"S1017","volume":"63","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone EC, Kremer JM, Zerbini CAF, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study. Arthritis Rheum. 2011;63(10):S1017\u20138.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"259_CR56","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96. doi:\n                    10.1186\/ar2297\n                    \n                  .","journal-title":"Arthritis Res Ther"},{"issue":"9672","key":"259_CR57","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0140-6736(09)60776-5","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A. Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. (vol 373, pg 633, 2009). Lancet. 2009;373(9672):1340.","journal-title":"Lancet"},{"issue":"12","key":"259_CR58","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1084\/jem.20061775","volume":"203","author":"K Sato","year":"2006","unstructured":"Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673\u201382. doi:\n                    10.1084\/Jem.20061775\n                    \n                  .","journal-title":"J Exp Med"},{"issue":"1","key":"259_CR59","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1476-9255-8-22","volume":"8","author":"AM Miller","year":"2011","unstructured":"Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22. doi:\n                    10.1186\/1476-9255-8-22\n                    \n                  .","journal-title":"J Inflamm (Lond)"},{"issue":"11","key":"259_CR60","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.4049\/jimmunol.1003487","volume":"186","author":"MM Zaiss","year":"2011","unstructured":"Zaiss MM, Kurowska-Stolarska M, Bohm C, Gary R, Scholtysek C, Stolarski B, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol. 2011;186(11):6097\u2013105. doi:\n                    10.4049\/jimmunol.1003487\n                    \n                  .","journal-title":"J Immunol"},{"key":"259_CR61","doi-asserted-by":"publisher","first-page":"819467","DOI":"10.1155\/2012\/819467","volume":"2012","author":"JC Waite","year":"2012","unstructured":"Waite JC, Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflamm. 2012;2012:819467. doi:\n                    10.1155\/2012\/819467\n                    \n                  .","journal-title":"Int J Inflamm"},{"issue":"3","key":"259_CR62","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/ar2438","volume":"10","author":"R Alten","year":"2008","unstructured":"Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67. doi:\n                    10.1186\/ar2438\n                    \n                  .","journal-title":"Arthritis Res Ther"},{"key":"259_CR63","doi-asserted-by":"publisher","unstructured":"Zhao B, Grimes SN, Li S, Hu X, Ivashkiv LB. TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med. 2012. doi:\n                    10.1084\/jem.20111566\n                    \n                  .","DOI":"10.1084\/jem.20111566"},{"issue":"1","key":"259_CR64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.febslet.2009.11.043","volume":"584","author":"H Park","year":"2010","unstructured":"Park H, No AL, Lee JM, Chen L, Lee SY, Lee DS, et al. PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts. FEBS Lett. 2010;584(1):173\u201380. doi:\n                    10.1016\/j.febslet.2009.11.043\n                    \n                  .","journal-title":"FEBS Lett"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-012-0259-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-012-0259-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11926-012-0259-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-012-0259-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T20:31:52Z","timestamp":1548189112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-012-0259-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,17]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1007\/s11926-012-0259-1","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,17]]}}}